4 results match your criteria: "California Dermatology Institute[Affiliation]"
A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome.
Blood
July 2024
Centre de Référence des Neutropénies Chroniques, Assistance Publique-Hôpitaux de Paris Sorbonne Université-Hôpital d'Enfants Armand-Trousseau, Paris, France.
Article Synopsis
- A phase 3 trial was conducted to evaluate the efficacy and safety of mavorixafor, an oral medication, in individuals with WHIM syndrome, a rare immunodeficiency disorder caused by genetic mutations.
- Participants were randomly assigned to receive either mavorixafor or a placebo for 52 weeks, with the study focusing on the time above certain white blood cell counts as the primary endpoint.
- Results showed mavorixafor significantly increased white blood cell counts, reduced infection rates and severity, and was well tolerated without serious adverse events occurring during the study.
Correction to: Dehydrated human amnion/chorion membrane allograft for postoperative wounds following Mohs micrographic surgery: a retrospective comparative evaluation.
Wounds
February 2024
Clinical Trials Research Institute, Thousand Oaks, CA; California Dermatology Institute, Thousand Oaks, CA.
Dehydrated human amnion/chorion membrane allograft for postoperative wounds following Mohs micrographic surgery: a retrospective comparative evaluation.
Wounds
September 2023
Clinical Trials Research Institute, Thousand Oaks, CA; California Dermatology Institute, Thousand Oaks, CA.
Introduction: Defects that remain after MMS cannot always be repaired immediately. When closure is not feasible, wounds are left to heal by secondary intention and may take weeks to close. In such cases, the use of an allograft that stimulates endogenous wound healing pathways may be desirable.
View Article and Find Full Text PDFDermatology TikTok™ videos: applicable considerations.
Clin Exp Dermatol
March 2023
California Dermatology Institute, CA, USA.